



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2024/025996

(22) International Filing Date:
24 April 2024 (24.04.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/498,049 25 April 2023 (25.04.2023) US
63/515,229 24 July 2023 (24.07.2023) US
63/550,274 06 February 2024 (06.02.2024) US
63/550,228 06 February 2024 (06.02.2024) US
63/557,039 23 February 2024 (23.02.2024) US

(71) Applicant: **AGLAEAPHARMA INC.** [US/US]; 20400
Century Blvd., Suite 120, Germantown, MD 20874 (US).

(72) Inventor; and

(71) Applicant: **ZHU, Lingyu**; 19 Brannegan Drive, Paw-
catuck, CT 06379 (US).

(72) Inventor: **CHENG, Zhiqiang**; 10105 Maplewood Drive,
Ellicott City, MD 21042 (US).

(74) Agent: **HE, Ming**; ICE MILLER LLP, 1735 Market Street,
Suite 3900, Philadelphia, Pennsylvania 19103 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(54) Title: IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREOF, AND USES THEREOF




FIG. 1C

(57) Abstract: The present disclosure relates to novel alpha2 adrenergic receptor (α 2AR) agonists and uses thereof. In particular, the present disclosure relates to imidazole containing compounds, in particular, of formula (I-A), formula (I-B), formula (I-C), formula (I-D), or formula (II). These compounds can be useful as peripherally selective α 2AR agonists for the treatment or prevention of disease thereof.